Document Detail


Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases.
MedLine Citation:
PMID:  9647304     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To describe the long term efficacy and side effects of the treatment of hemifacial spasm with Dysport and to evaluate two different sites of injection to hopefully reduce side effects. METHODS: This study was designed as a prospective descriptive study. Injections were made subcutaneously around the eye. Peak improvement was subjectively assessed by using a visual analogue scale and reported in percentages (0-100%). Duration of improvement was assessed subjectively and reported in months. RESULTS: Of 175 cases, 17 were lost to follow up and were excluded. 855 treatments were injected in the remaining 158 patients with a median of 4 treatments. The response rate was 97%. Of 855 treatments, the adjusted mean peak and duration of improvement was 77.2 (95% confidence interval (95%CI) 74.7-79.4)% and 3.4 (95%CI 3.2-3.6) months respectively. In 158 patients (complete group), the long term results from the first to the 12th treatment showed that the mean peak improvement ranged from 72.70 to 80.10% and the duration of improvement was 2.60 to 3.71 months. It remained constant throughout (p=0.40, p=0.87 respectively). The most common side effect was ptosis. Of the 158 patients, 21 completed 12 treatments (subgroup). A separate analysis of this group disclosed a mean peak and duration of improvement from the first to 12th treatments ranging from 70.00 to 78.10% and 2.65 to 4.31 months respectively. Analysis of variance with repeated measures showed no significant variation of peak and duration of improvement over the first to the 12th treatments (p=0.38, p=0.38 respectively). Only 3% of the treatments were unsuccessful but responded to subsequent treatments. The incidence of ptosis was reduced from 27.17% to 9.68% by moving the injection site to the lateral part of orbital orbicularis oculi without any loss of efficacy. The yearly cost of Dysport is considerably less than Botox. CONCLUSION: This study is the first to show, in detail, the long term results of treatments of hemifacial spasm with Dysport. The efficacy is constant throughout orbicularis oculi. The efficacy of Dysport is comparable with Botox in long term follow up.
Authors:
S Jitpimolmard; S Tiamkao; M Laopaiboon
Related Documents :
3676924 - Local treatment of spasmodic torticollis with botulinum toxin.
19787394 - Artefill permanent injectable for soft tissue augmentation: i. mechanism of action and ...
16215314 - Effectiveness of urethral injection of botulinum a toxin in the treatment of voiding dy...
2609244 - Intracavernous self-injection of prostaglandin e1 in the therapy of erectile dysfunction.
8565664 - Evaluation of a tubular mesh and a spiral stent woven from titanium nickel alloy for pr...
7444244 - Criteria for evaluation of therapeutic response to antifungal drugs.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of neurology, neurosurgery, and psychiatry     Volume:  64     ISSN:  0022-3050     ISO Abbreviation:  J. Neurol. Neurosurg. Psychiatr.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-07-23     Completed Date:  1998-07-23     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  2985191R     Medline TA:  J Neurol Neurosurg Psychiatry     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  751-7     Citation Subset:  IM    
Affiliation:
Department of Medicine, Faculty of Medicine, Khon Kaen University, Thailand. Suthip-J@Medlib2.kku.ac.th
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Analysis of Variance
Botulinum Toxin Type A / therapeutic use*
Female
Follow-Up Studies
Hemifacial Spasm / drug therapy*
Humans
Male
Middle Aged
Neuromuscular Agents / therapeutic use*
Prospective Studies
Time Factors
Chemical
Reg. No./Substance:
0/Botulinum Toxin Type A; 0/Neuromuscular Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed i...
Next Document:  Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington'...